Now Available for Public Comment: Notice of Proposed Rulemaking (NPRM) for FDAAA 801 and NIH Draft Reporting Policy for NIH-Funded Trials
8 studies found for:    curevac
Show Display Options
Rank Status Study
1 Recruiting Safety and Tolerability of CV8102 Alone and in Combination With a Rabies Virus Vaccine in Healthy Adults
Condition: Rabies
Interventions: Biological: CV8102;   Biological: Rabipur;   Biological: CV8102 + Rabipur
2 Recruiting An Open Label Randomised Trial of RNActive® Cancer Vaccine in High Risk and Intermediate Risk Patients With Prostate Cancer
Condition: Prostate Carcinoma
Interventions: Biological: CV9104;   Device: needle free injection device (TropisTM)
3 Active, not recruiting Trial of RNActive®-Derived Prostate Cancer Vaccine in Metastatic Castrate-refractory Prostate Cancer
Condition: Prostate Cancer
Interventions: Biological: CV9104;   Biological: Placebo
4 Completed Safety and Efficacy Trial of a RNActive®-Derived Prostate Cancer Vaccine in Hormone Refractory Disease
Condition: Hormonal Refractory Prostate Cancer
Intervention: Biological: CV9103
5 Completed Trial of an RNActive®-Derived Cancer Vaccine in Stage IIIB/IV Non Small Cell Lung Cancer (NSCLC)
Condition: Non Small Cell Lung Cancer
Intervention: Biological: CV9201
6 Recruiting RNActive® Rabies Vaccine (CV7201) in Healthy Adults
Condition: Rabies
Intervention: Biological: CV7201 mRNA
7 Recruiting Trial of RNActive®-Derived Cancer Vaccine and Local Radiation in in Stage IV Non Small Cell Lung Cancer (NSCLC)
Condition: Non-Small Cell Lung Carcinoma
Intervention: Biological: CV9202
8 Terminated
Has Results
RNActive®-Derived Therapeutic Vaccine
Condition: Hormone Refractory Prostate Cancer
Intervention: Biological: CV9103

Indicates status has not been verified in more than two years